Financial Performance - Tianda Pharmaceuticals reported a revenue of HKD 1.2 billion for the fiscal year 2022, representing a year-on-year increase of 15%[4] - The company achieved a net profit of HKD 250 million, which is a 20% increase compared to the previous year[4] - The Group achieved total revenue of HK$510.0 million for the fiscal year 2022, representing an increase of HK$35.7 million or 7.5% year-on-year[62] - Revenue from the Pharmaceuticals and medical technologies segment was HK$396.1 million, an increase of HK$38.4 million or 10.7% year-on-year[63] - For the fiscal year ended 2022, the revenue for the Medical and healthcare services segment was HK$7.4 million, representing a year-over-year increase of HK$2.7 million or 57.4%[69] - Gross profit decreased from HK$259.0 million to HK$241.2 million, primarily due to a decrease in unit price and gross profit of Tuoping® Valsartan capsules[76] - Selling and distribution expenses decreased from HK$211.7 million to HK$198.0 million for the fiscal year ended 2022[76] - Administrative expenses rose from HK$69.8 million to HK$71.5 million, mainly due to increased staff remuneration expenses[77] - Other income and net gains increased from HK$7.5 million to HK$16.8 million, primarily due to a one-off gain of HK$12.1 million from the disposal of a subsidiary[82] - Loss attributable to owners of the parent decreased from HK$27.1 million to HK$19.8 million for the fiscal year ended 2022[83] Future Projections - For the upcoming fiscal year, Tianda Pharmaceuticals projects a revenue growth of 10% to 12%, targeting HKD 1.32 billion to HKD 1.344 billion[4] - The company is investing HKD 100 million in R&D for new product development, focusing on innovative pharmaceutical solutions[4] - Tianda Pharmaceuticals plans to expand its market presence in Southeast Asia, aiming for a 25% increase in market share by 2025[4] Product Development and Innovation - The company has established a strategic partnership with a leading biotech firm to enhance its research capabilities and accelerate product development[4] - Tianda Pharmaceuticals has launched two new products in the Chinese market, contributing to a 5% increase in sales in Q4 2022[4] - The Group aims to enhance its product line and improve the quality and quantity of R&D projects through external introduction, research and development, and acquisitions[62] Awards and Recognition - Tianda Pharmaceuticals was awarded the "Outstanding Brand Awards 2021" for Chinese Medicine Services[19] - The "TDMall on Cloud" App won the Hong Kong Business Technology Excellence Awards 2021 for Mobile Healthcare Technology[19] - Tianda Pharmaceuticals won the "Best Mid and Small Caps Company" award for two consecutive years[19] Corporate Governance - The Company has complied with the Corporate Governance Code during the fiscal year 2022, except for the separation of the roles of Chairman and CEO[100] - The Board consists of 7 Directors, including 2 Executive Directors, 2 Non-executive Directors, and 3 Independent Non-executive Directors[108] - The Company has established a Nomination Committee comprising two INEDs and one Executive Director, with no new director appointed during FYE2022[138] - The Company encourages continuous professional development for all Directors to enhance their knowledge and skills[123] Risk Management and Internal Control - The Company has established an internal audit department to assess risk management and internal control systems, reporting findings to the Audit Committee and senior management regularly[200] - The risk management and internal control systems are designed to manage risks associated with achieving corporate objectives[199] - The Company emphasizes safeguarding shareholders' investments and assets through effective risk management[199] Financial Resources and Capital Structure - As of March 31, 2022, the Group had cash and cash equivalents of approximately HK$334.0 million, up from HK$235.0 million the previous year[84] - The Group has sufficient financial resources to support operational and capital expenditures[85] - The Group has no net debt as the total borrowings are less than cash and cash equivalents[87] Market Strategy - The Group's strategy focuses on the development of Chinese medicine, innovative drugs, and quality medical services, implementing the "3D+1S" initiatives[49] - The Group plans to expand its modern Chinese medical clinic "TDMall" through self-construction, franchising, and mergers and acquisitions, focusing on the Guangdong-Hong Kong-Macao Greater Bay Area[56] - The Group's efforts in the Chinese medicine sector include trading of Chinese medicinal materials and production of TCM decoction pieces, forming a nationwide and global business network[64]
天大药业(00455) - 2022 - 年度财报